tradingkey.logo
搜索

AIM ImmunoTech Inc

AIM
添加自选
0.257USD
+0.022+9.45%
收盘 07-31 16:00美东报价延迟15分钟
2.12M总市值
亏损市盈率 TTM

关于 AIM ImmunoTech Inc 公司

AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

AIM ImmunoTech Inc简介

公司代码AIM
公司名称AIM ImmunoTech Inc
上市日期Jul 12, 1996
CEOEquels (Thomas K)
员工数量21
证券类型Ordinary Share
年结日Jul 12
公司地址2117 Sw Highway 484
城市OCALA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编32801
电话13524487797
网址https://aimimmuno.com/
公司代码AIM
上市日期Jul 12, 1996
CEOEquels (Thomas K)

AIM ImmunoTech Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
63.92K
--
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
28.44K
--
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
--
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
--
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--

常见问题

AIM ImmunoTech Inc的前五大股东是谁?

AIM ImmunoTech Inc 的前五大股东如下:Mr. Thomas K. Equels, Esq., J.D.

有多少机构持有AIM ImmunoTech Inc(AIM)的股份?

截至2026Q1,共有57家机构持有AIM ImmunoTech Inc的股份,合计持有的股份价值约为105.74K,占公司总股份的1.30%。与2025Q4相比,机构持股有所增加,增幅为-74291.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有